Sofwave to host showcase booth from September 1-4Facial and neck treatment workshop held on September 2SUPERB neck, skin, and eyebrow...
HONG KONG, Aug. 25, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,...
MURRAY, Utah, Aug. 25, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), announced today a 10-year partnership with...
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on...
Issued claims will protect use of a biomarker to assess response to Lomecel-B™ in patients with blood vessel dysfunctionMIAMI, Aug....
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”)...
Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials The MAGNOLIA study will compare abelacimab...
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock...
MINNEAPOLIS, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
Ublituximab is an investigational targeted B-cell therapy that shows superior efficacy when compared with teriflunomide, a commonly prescribed oral treatment...
Expanding services and offerings to the infectious disease community throughout the U.S. provides revenue growth opportunityServices at launch include rapid...
Jushi Opens Fourth Dispensary in Virginia Jushi Holdings Inc. announced the opening of its fourth medical cannabis dispensary in Virginia...
– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA – – First...
Patient denied testing for weeks due to risk of physician infection & non-MSM status Amerimmune Long COVID Panel and Provista...
First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission on Track for Fourth Quarter...
ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to...
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S....
WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
– Company boasts highest second quarter sales to date; Q2 2022 sales of $5,500,000 vs $4,409,000 in Q2 2021, a...
August 29 webinar will detail the research and success of the clinical trial from the Sagol CenterORLANDO, Fla., Aug. 24,...